ArticleThe British journal of radiology2014
Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer.
Article in The British journal of radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- MRI-Derived Biomarkers and Radiomic Signatures for Early, Dose-Dependent Evaluation of Prostate Cancer Radiotherapy: An Exploratory Study.Journal of imaging · 2026Article
- Apparent diffusion coefficient as a quantitative biomarker for prostate cancer treatment response on a 1.5 Tesla magnetic resonance-linear accelerator: Impact of image registration and acquisition type.Physics and imaging in radiation oncology · 2025Article
- Article
- Anatomical zone and tissue type impacts the repeatability of quantitative MRI parameters and radiomic features for longitudinal monitoring of treatment response in the prostate.Magma (New York, N.Y.) · 2025Article
- From CBCT to MR-Linac in Image-Guided Prostate Cancer Radiotherapy Towards Treatment Personalization.Current oncology (Toronto, Ont.) · 2025Review
- Article
- Article
- Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer.Clinical radiology · 2024Article
- Multi-parametric MRI for radiotherapy simulation.Medical physics · 2023Review
- Article
- MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.The British journal of radiology · 2022Review
- Review
- Role and future of MRI in radiation oncology.The British journal of radiology · 2019Review
- Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO).Radiation oncology (London, England) · 2019Article
- Changes in prostate apparent diffusion coefficient values during radiotherapy after neoadjuvant hormones.Therapeutic advances in urology · 2018Article
- The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.International journal of radiation oncology, biology, physics · 2018Review
- Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer.Scientific reports · 2018Article
- Diffusion MRI in early cancer therapeutic response assessment.NMR in biomedicine · 2017Review
- Biological imaging in clinical oncology: radiation therapy based on functional imaging.International journal of clinical oncology · 2016Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to assess the efficacy of diffusion-weighted MRI (DWI) in monitoring response to radiotherapy in high-risk prostate cancer (PC).
methodsThis retrospective study included 78 patients with high-risk PC undergoing 3.0-T MRI (supplemented by DWI) before and after intensity-modulated radiotherapy (IMRT). Based on follow-up clinical examinations, patients were divided into two groups: the recurrence group (patients who suffered biochemical/clinical recurrence within 3 years, n = 13) and the non-recurrence group (patients who were recurrence free for over 3 years, n = 65). The apparent diffusion coefficient (ADC) values before and after IMRT were compared between these two groups. The receiver-operating characteristics (ROC) analysis was carried out to investigate the discriminatory capability for pre- and post-IMRT ADC values.
resultsThe overall ADC values were 1.04 ± 0.18 × 10(-3) mm(2) s(-1) for PCs before IMRT and 1.45 ± 0.15 × 10(-3) mm(2) s(-1) after IMRT (p < 0.001). A statistically significant difference in post-IMRT ADC values was noted between patients with and without recurrence (1.27 ± 0.14 × 10(-3) mm(2) s(-1) vs 1.49 ± 0.12 × 10(-3)mm(2) s(-1); p < 0.001), although there was no statistical difference between them in pre-IMRT ADC values (1.00 ± 0.17 × 10(-3) mm(2) s(-1) vs 1.05 ± 0.18 × 10(-3) mm(2) s(-1); p = 0.31). The ROC curve analysis revealed that the post-IMRT ADC values could help identify patients suffering recurrences (area under the curve, 0.88; p < 0.001).
conclusionMarked increase in ADC values was observed in PC after radiotherapy, especially in good responders. DWI is a valuable tool for monitoring the response to radiotherapy. ADVANCES IN KNOWLEDGE: This study examined the relationship between ADC changes and tumour response to treatment of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.